Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about 2% premarket. “Lacking…
Browsing: nearterm
Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about 2% premarket. “Lacking…
Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about 2% premarket. “Lacking…